サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1684128

ゲノムがんパネルとプロファイリング市場：がん別、用途別、組織別、遺伝子タイプ別、潜在市場規模 - エグゼクティブコンサルタントガイド付き（2025年～2029年）

Genomic Cancer Panel and Profiling Markets by Cancer, by Application, by Tissue and by Gene Type with Screening Potential Market Size. With Executive and Consultant Guides 2025-2029

出版日
ページ情報
英文 585 Pages
納期
即日から翌営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
ゲノムがんパネルとプロファイリング市場：がん別、用途別、組織別、遺伝子タイプ別、潜在市場規模 - エグゼクティブコンサルタントガイド付き（2025年～2029年）
出版日: 2025年03月07日
発行: Howe Sound Research
ページ情報: 英文 585 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がん遺伝子パネルとゲノムプロファイリングは、がんの診断と治療を急速に変えつつあります。そして今、人工知能が新たな扉を開きつつあります。がん専門医ががんに関連する何100もの遺伝子の情報を日常的に使用し始めるにつれて、市場は専門的なニッチから主流へと移行しつつあります。市場は2つの異なるセグメントで爆発的に成長しています

包括的パネル、ゲノムプロファイリング、高リスク乳がんパネル。ゼロから創造された市場で、参入企業がどのようにポジションを争っているのか、また、一部の参入企業は大きくリードし、世界に展開しています。それは、適切な診断薬と適切なサポートがプレミアム価格を可能にする、大きな機会を秘めたダイナミックな市場状況です。そして、科学が開発されると同時に、定期的に新たな機会が生み出されています。シーケンシングのコストは下がり続けています。

当レポートは、世界のゲノムがんパネルとプロファイリング市場について調査し、18ヶ国および4地域の詳細な内訳とともに、がんタイプ別、用途別、組織別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場ガイド

第2章 イントロダクションと市場の定義

  • がん遺伝子パネルとプロファイリングとは何か
  • シーケンシング革命
  • 市場の定義
  • 調査手法
  • 視点：ヘルスケア費支出

第3章 市場概要

  • 市場参入組織
    • 学術研究機関
    • 診断試験開発者
    • 計測機器サプライヤー
    • 化学薬品/試薬サプライヤー
    • 病理サプライヤー
    • 独立系臨床検査室
    • 公共の国立/地域研究所
    • 病院検査室
    • 臨床検査室
    • 監査機関
    • 認証機関
  • 腫瘍ゲノム学
  • がんの管理と診断
  • 導入の段階- 将来見通し
  • 産業構造の影響
  • 現在利用可能な大規模包括的アッセイ
  • プロファイリングと全エクソーム（またはゲノム）シーケンシングの価格設定

第4章 市場動向

  • 成長促進要因
  • 成長抑制要因
  • 計測と自動化
  • 診断技術開発

第5章 がんパネルとプロファイルの最近の動向

第6章 主要企業のプロファイル

  • 10x Genomics, Inc.
  • Abbott Laboratories
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Aethlon Medical
  • Agilent
  • Amoy Diagnostics Co., Ltd.
  • Anchor Dx
  • ANGLE plc
  • ARUP Laboratories
  • AVIVA Systems Biology
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics（Danaher）
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • BioIVT
  • Biolidics Ltd
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bristol-Myers Squibb
  • Burning Rock
  • C2i Genomics
  • Cardiff Oncology
  • Caris Molecular Diagnostics
  • Castle Biosciences, Inc.
  • Celemics
  • CellMax Life
  • Cepheid（Danaher）
  • Charles River Laboratories
  • Circulogene
  • Clearbridge Biomedics
  • Clinical Genomics
  • Cytolumina Technologies Corp.
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Element Biosciences
  • Enzo Biochem
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exact Sciences
  • Fabric Genomics
  • Fluxion Biosciences（Cell Microsystems）
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • GeneDx Holdings
  • GeneFirst Ltd.
  • Genetic Technologies Ltd.
  • Genetron Holdings
  • GenomOncology
  • GILUPI Nanomedizin
  • Guardant Health
  • HansaBiomed
  • HTG Molecular Diagnostics
  • iCellate
  • ICON PLC
  • Illumina
  • Incell Dx
  • Inivata
  • Invitae Corporation
  • Invivogen
  • Invivoscribe
  • J&J Innovative Medicine
  • KEW
  • Lucence Health
  • Lunglife AI Inc
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Menarini Silicon Biosystems
  • Mesa Laboratories, Inc.
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Myriad Genetics
  • Nanostring
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • NGeneBio
  • Novogene
  • Oncimmune
  • Oncocyte
  • OncoDNA
  • OraLiva
  • Oxford Nanopore Technologies
  • Panagene
  • Personalis
  • Perthera
  • PGDx（Labcorp）
  • Precipio
  • PrecisionMed
  • Predictive Oncology
  • Prenetics
  • Promega
  • Qiagen
  • QuidelOrtho
  • Rarecells SAS
  • RareCyte
  • Revvity
  • Roche Diagnostics
  • Screencell
  • Sherlock Biosciences
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singular Genomics
  • Singulomics
  • SkylineDx
  • Standard BioTools
  • Stilla Technologies
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific
  • Todos Medical
  • Ultima Genomics
  • Variantyx
  • Vela Diagnostics
  • Veracyte
  • VolitionRX
  • Vortex Biosciences

第7章 がん遺伝子パネルとプロファイルの世界市場

  • 国別世界市場概要
  • がんタイプ別世界市場- 概要
  • 用途別世界市場- 概要
  • 組織別世界市場- 概要
  • 世界市場生殖細胞および体細胞- 概要

第8章 世界のがん遺伝子パネルとプロファイル市場- がんタイプ別

  • 包括的なパネルとプロファイル
  • 乳がん遺伝子検査
  • 大腸がん遺伝子検査
  • 婦人科がん遺伝子検査
  • 血液がん遺伝子検査
  • 前立腺がん遺伝子検査
  • 肺がん遺伝子検査
  • その他のがん遺伝子検査

第9章 世界のがん遺伝子パネルとプロファイル市場- 用途別

  • 臨床試験
  • 医薬品試験
  • 研究試験

第10章 世界のがん遺伝子パネルとプロファイル市場- 組織タイプ別

  • 固形組織
  • 液体組織検査

第11章 世界のがん遺伝子検査市場- 生殖細胞系および体細胞系

  • 世界市場 - 体細胞
  • 世界市場 - 生殖細胞

第12章 潜在的市場機会の規模

第13章 付録

図表

Table of Tables

  • Table 1: Market Players by Type
  • Table 2: The Base Pairs
  • Table 3: Current Assays
  • Table 4: Relevant Pricing Table
  • Table 5: Five Factors Driving Growth
  • Table 6: Four Factors Limiting Growth
  • Table 7: Key Diagnostic Laboratory Technology Trends
  • Table 8: Next Generation Sequencing Technologies - Speed and Cost
  • Table 9: Global Cancer Panel Market by Region
  • Table 10: Global Market by Cancer Type
  • Table 11: Global Market by Application
  • Table 12: Global Market by Tissue
  • Table 13: Global Market Germline & Somatic
  • Table 14: Comprehensive Testing by Country
  • Table 15: Breast Cancer Gene Testing by Country
  • Table 16: Colorectal Cancer Gene Testing by Country
  • Table 17: Gynecological Cancer Testing by Country
  • Table 18: Blood Cancer Gene Testing by Country
  • Table 19: Prostate Cancer Gene Testing by Country
  • Table 20: Lung Cancer Gene Testing by Country
  • Table 21: Other Cancer Gene Testing by Country
  • Table 22: Clinical Testing by Country
  • Table 23: Pharmaceutical Testing by Country
  • Table 24: Research Testing by Country
  • Table 25: Solid Tissue Testing by Country
  • Table 26: Liquid Tissue Testing by Country
  • Table 27: Somatic by Country
  • Table 28: Germline by Country
  • Table 29: Potential Screening Market: Lung, Breast & Colorectal
  • Table 30: Potential Screening Market: Prostate, Other & All
  • Table 31: Potential Cancer Diagnosis Market Size
  • Table 32: Potential Cancer Management Market Size
  • Table 33: The Most Common Assays
  • Table 34: Largest Revenue Assays
  • Table 35: Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: VistSeq Hereditary Cancer Panel
  • Figure 2: Global Healthcare Spending
  • Figure 3: The Road to Diagnostics
  • Figure 4: The Genomic Progression of Cancer
  • Figure 5: DNA Strands and Chromosomes
  • Figure 6: Karyogram of Human Chromosomes
  • Figure 7: Size of Various Genomes
  • Figure 8: Germline vs Somatic Mutations
  • Figure 9: Comparing Genomic Diagnostic and Traditional Testing
  • Figure 10: The Changing Age of The World's Population
  • Figure 11: Health Care Consumption by Age
  • Figure 12: Cancer Incidence - Age at Diagnosis
  • Figure 13: Base Year Country Global Share
  • Figure 14: Global Market by Cancer - Base vs. Final Year
  • Figure 15: Cancer Panel Market Base Year
  • Figure 16: Cancer Panel Market Final Year
  • Figure 17: Cancer Type Share by Year
  • Figure 18: Cancer Type Segment Growth
  • Figure 19: Global Market by Cancer - Base vs. Final Year
  • Figure 20: Cancer Panel Market Base Year
  • Figure 21: Cancer Panel Market Final Year
  • Figure 22: Application Share by Year
  • Figure 23: Application Segment Growth
  • Figure 24: Global Market by Cancer - Base vs. Final Year
  • Figure 25: Cancer Panel Market Base Year
  • Figure 26: Cancer Panel Market Final Year
  • Figure 27: Tissue Share by Year
  • Figure 28: Tissue Segment Growth
  • Figure 29: Germline & Somatic - Base vs. Final Year
  • Figure 30: Germline & Somatic Market Base Year
  • Figure 31: Germline & Somatic Market Final Year
  • Figure 32: Germline & Somatic Share by Year
  • Figure 33: Germline & Somatic Segment Growth
  • Figure 34: Comprehensive Testing Growth
  • Figure 35: Breast Cancer Testing Growth
  • Figure 36: Colorectal Cancer Gene Testing Growth
  • Figure 37: Gynecological Cancer Testing Growth
  • Figure 38: Blood Cancer Gene Testing Growth
  • Figure 39: Prostate Cancer Gene Testing Growth
  • Figure 40: Lung Cancer Gene Testing Growth
  • Figure 41: Other Cancer Gene Testing Growth
  • Figure 42: Clinical Testing Growth
  • Figure 43: Pharmaceutical Testing Growth
  • Figure 44: Research Testing Growth
  • Figure 45: Solid Tissue Testing Growth
  • Figure 46: Liquid Tissue Testing Growth
  • Figure 47: Somatic Testing Growth
  • Figure 48: Germline Testing Growth
  • Figure 49: IVD Test Menu Growth
  • Figure 50: IVD Test Average Fees - A Ten Year View
目次

OVERVIEW:

Cancer Gene Panels and Genomic Profiling are quickly changing the diagnosis and treatment of cancers. And now Artificial Intelligence is opening new doors. The market is moving out of a specialized niche and going mainstream as Oncologists begin routinely using information on the hundreds of genes related to cancer. The market is exploding in two distinct segments. Find out how this new way of understanding cancer will change cancer diagnostics forever.

Comprehensive panels, genomic profiling, high risk breast cancer panels. Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are pulling way out in front and expanding globally. It is a dynamic market situation with enormous opportunity where the right diagnostic with the right support can command premium pricing. And the science is developing at the same time creating new opportunities with regularity. And the cost of sequencing continues to fall.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Table of Contents

1. Market Guides

  • 1.1. Cancer Panel Market - Strategic Situation Analysis
  • 1.2. Large Comprehensive Cancer Panel Market - Situation Analysis
  • 1.3. Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.4. Guide for Management Consultants and Investment Advisors
  • 1.5. Impact of Artificial Intelligence on Cancer Profiling Market

2. Introduction and Market Definition

  • 2.1. What are Cancer Gene Panels and Profiling?
  • 2.2. The Sequencing Revolution
  • 2.3. Market Definition
    • 2.3.1. Revenue Market Size
  • 2.4. Methodology
    • 2.4.1. Methodology
    • 2.4.2. Sources
    • 2.4.3. Authors
  • 2.5. Perspective: Healthcare Spending
    • 2.5.1. Global Healthcare Spending
    • 2.5.2. Spending on Healthcare and Pharmaceuticals
    • 2.5.3. Spending on Diagnostics
    • 2.5.4. Important Role of Insurance for Medical Services

3. Market Overview

  • 3.1. Players in a Dynamic Market
    • 3.1.1. Academic Research Lab
    • 3.1.2. Diagnostic Test Developer
    • 3.1.3. Instrumentation Supplier
    • 3.1.4. Chemical/Reagent Supplier
    • 3.1.5. Pathology Supplier
    • 3.1.6. Independent Clinical Laboratory
    • 3.1.7. Public National/regional Laboratory
    • 3.1.8. Hospital Laboratory
    • 3.1.9. Physicians Office Lab (POLS)
    • 3.1.10. Audit Body
    • 3.1.11. Certification Body
  • 3.2. Oncogenomics
    • 3.2.1. Carcinogenesis
    • 3.2.2. Chromosomes, Genes and Epigenetics
      • 3.2.2.1. Chromosomes
      • 3.2.2.2. Genes
      • 3.2.2.3. Epigenetics
    • 3.2.3. Cancer Genes
    • 3.2.4. Germline vs Somatic
    • 3.2.5. Gene Panels, Single Gene Assays and Multiplexing
    • 3.2.6. Genomic Profiling
    • 3.2.7. The Comprehensive Assay
    • 3.2.8. Changing Clinical Role
    • 3.2.9. The Cancer Screening Market Opportunity
  • 3.3. Cancer Management vs. Diagnosis
    • 3.3.1. The Role of Risk Assessment
    • 3.3.2. Diagnosis
    • 3.3.3. Managing
    • 3.3.4. Monitoring
  • 3.4. Phases of Adoption - Looking into The Future
  • 3.5. Structure of Industry Plays a Part
    • 3.5.1. Hospital Testing Share
    • 3.5.2. Economies of Scale
      • 3.5.2.1. Hospital vs. Central Lab
    • 3.5.3. Physician Office Lab's
    • 3.5.4. Physician's and POCT
  • 3.6. Currently Available Large Comprehensive Assays
  • 3.7. Pricing Profiling vs. Whole Exome (or Genome) Sequencing
    • 3.7.1. Medicare Profile Pricing
    • 3.7.2. Whole Exome Sequencing

4. Market Trends

  • 4.1. Factors Driving Growth
    • 4.1.1. Level of Care
    • 4.1.2. Companion Dx
    • 4.1.3. Immuno-oncology
    • 4.1.4. Liability
    • 4.1.5. The Aging Effect
  • 4.2. Factors Limiting Growth
    • 4.2.1. State of knowledge
    • 4.2.2. Genetic Blizzard
    • 4.2.3. Protocol Resistance
    • 4.2.4. Regulation and coverage
  • 4.3. Instrumentation and Automation
    • 4.3.1. Instruments Key to Market Share
    • 4.3.2. Bioinformatics Plays a Role
  • 4.4. Diagnostic Technology Development
    • 4.4.1. Next Generation Sequencing Fuels a Revolution
    • 4.4.2. Single Cell Genomics Changes the Picture
    • 4.4.3. Pharmacogenomics Blurs Diagnosis and Treatment
    • 4.4.4. CGES Testing, A Brave New World
    • 4.4.5. Biochips/Giant magneto resistance based assay

5. Cancer Panels & Profiles Recent Developments

  • 5.1. Recent Developments - Importance and How to Use This Section
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
  • 5.2. Foundation Medicine, Fulgent Genetics to Launch Germline Testing
  • 5.3. Advanced Genomics APAC, 3BIGS Partner on Cancer Testing
  • 5.4. Lucence Assay Gets Coverage for Advanced Solid Tumors
  • 5.5. Foundation Medicine, AnHeart Therapeutics to Develop CDx for NSCLC Therapy
  • 5.6. Roche CGP Assay Shows Concordance With Other NGS-Based Assays
  • 5.7. Precede Biosciences Emerges From Stealth With $57M
  • 5.8. Geneseeq Nabs CE Marks for Cancer Test Kits
  • 5.9. Realm IDx Profiling Test Gets National Health Coverage in Japan
  • 5.10. Foundation Medicine, Merck KGaA to Collaborate on Companion Diagnostics
  • 5.11. Guardant Health Secures Coverage for Liquid Biopsy Profiling Test
  • 5.12. Myriad Genetics, Intermountain Precision Genomics Obtain NY Certification for Tumor Profiling
  • 5.13. Cota, Genomic Testing Coop Ink Oncology Partnership
  • 5.14. Euformatics, ViennaLab, Oncompass Win Liquid Biopsy Development Contract
  • 5.15. Prenetics' Cancer Profiling Test Receives FDA Clearance
  • 5.16. Genetic Profiling May Identify Patients Who Do Not Need Radiation Therapy
  • 5.17. Thermo Fisher Introduces Homologous Score for Cancer Profiling
  • 5.18. Genomic Test IDs Cancer Cells Early
  • 5.19. Caris Life Sciences to Offer Molecular Profiling Services
  • 5.20. Geneseeq to Build Lab for Cancer Profiling in Brazil
  • 5.21. Genetron Health Adds New Assays to Pipeline
  • 5.22. Illumina Obtains CE-IVD Marking for TSO Comprehensive Assay
  • 5.23. Guardant Health Receives Medicare Coverage for Guardant360 TissueNext(TM) Test
  • 5.24. Cancer Screening Launch Approaches, Guardant Health Plans New Comprehensive Assay
  • 5.25. Thermo Fisher, Oncocyte Ink Deal for Cancer IVDs
  • 5.26. Local Cancer Genomic Profiling Options Grow, Though Central Labs Will Likely Keep Major Role
  • 5.27. Labcorp, CCORN Partner for Precision Oncology
  • 5.28. Dante Labs Acquires Cambridge Cancer Genomics
  • 5.29. Celemics, Strand Partner on Integrated Platform for NGS Analysis
  • 5.30. Myriad Genetics Recalibrates Breast Cancer Panel for All Ancestries
  • 5.31. Burning Rock Revenues Rise
  • 5.32. Caris Life Sciences to Expand Liquid Biopsy Testing
  • 5.33. OncoDiag Announces Multiplex Test for Bladder Cancer Recurrence
  • 5.34. Intermountain and Myriad Combine Test Offering
  • 5.35. Illumina, Geneseeq to Offer Cancer Testing Kits in China
  • 5.36. Exact Sciences to Offer End-to-End Cancer Testing
  • 5.37. Guardant Health Turns to Tumor Tissue Sequencing
  • 5.38. Tempus Inks Oncology Testing Collaboration With Bayer
  • 5.39. Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform
  • 5.40. Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test
  • 5.41. Metastatic Cancer Markers Identified in Clinical WGS Study
  • 5.42. Stitch Bio Bets on CRISPR Tech
  • 5.43. Bayer, LifeLabs Launch Free NTRK Genetic Testing Program
  • 5.44. Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx
  • 5.45. Progress, Challenges in Liquid Biopsy Reimbursement
  • 5.46. Israeli Startup Curesponse Raises $6M
  • 5.47. Invitae, ArcherDX Merge to Advance Precision Oncology Offerings
  • 5.48. MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution
  • 5.49. NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program
  • 5.50. Germline Results Guides Precision Therapy in Advanced Cancer
  • 5.51. FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics
  • 5.52. ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers
  • 5.53. Labs Reporting Cancer Risk Mutations from Tumor Testing
  • 5.54. Users Begin Integrating Genomics Data for Clinical Decision Support
  • 5.55. Fujitsu Improves Efficiency in Cancer Genomic Medicine

6. Profiles of Key Players

  • 6.1. 10x Genomics, Inc.
  • 6.2. Abbott Laboratories
  • 6.3. AccuraGen Inc.
  • 6.4. Adaptive Biotechnologies
  • 6.5. Admera Health, LLC
  • 6.6. Aethlon Medical
  • 6.7. Agilent
  • 6.8. Amoy Diagnostics Co., Ltd.
  • 6.9. Anchor Dx
  • 6.10. ANGLE plc
  • 6.11. ARUP Laboratories
  • 6.12. AVIVA Systems Biology
  • 6.13. Baylor Miraca Genetics Laboratories
  • 6.14. Beckman Coulter Diagnostics (Danaher)
  • 6.15. Becton, Dickinson and Company
  • 6.16. BGI Genomics Co. Ltd
  • 6.17. Bioarray Genetics
  • 6.18. Biocartis
  • 6.19. Biocept, Inc.
  • 6.20. Biodesix Inc.
  • 6.21. BioFluidica
  • 6.22. BioGenex
  • 6.23. BioIVT
  • 6.24. Biolidics Ltd
  • 6.25. bioMerieux Diagnostics
  • 6.26. Bioneer Corporation
  • 6.27. Bio-Rad Laboratories, Inc
  • 6.28. Bio-Reference Laboratories
  • 6.29. Bio-Techne
  • 6.30. Bioview
  • 6.31. Bristol-Myers Squibb
  • 6.32. Burning Rock
  • 6.33. C2i Genomics
  • 6.34. Cardiff Oncology
  • 6.35. Caris Molecular Diagnostics
  • 6.36. Castle Biosciences, Inc.
  • 6.37. Celemics
  • 6.38. CellMax Life
  • 6.39. Cepheid (Danaher)
  • 6.40. Charles River Laboratories
  • 6.41. Circulogene
  • 6.42. Clearbridge Biomedics
  • 6.43. Clinical Genomics
  • 6.44. Cytolumina Technologies Corp.
  • 6.45. Datar Cancer Genetics Limited
  • 6.46. Diagnologix LLC
  • 6.47. Diasorin S.p.A.
  • 6.48. Element Biosciences
  • 6.49. Enzo Biochem
  • 6.50. Epic Sciences
  • 6.51. Epigenomics AG
  • 6.52. Eurofins Scientific
  • 6.53. Exact Sciences
  • 6.54. Fabric Genomics
  • 6.55. Fluxion Biosciences (Cell Microsystems)
  • 6.56. Freenome
  • 6.57. FUJIFILM Wako Diagnostics
  • 6.58. Fujirebio
  • 6.59. GeneDx Holdings
  • 6.60. GeneFirst Ltd.
  • 6.61. Genetic Technologies Ltd.
  • 6.62. Genetron Holdings
  • 6.63. GenomOncology
  • 6.64. GILUPI Nanomedizin
  • 6.65. Guardant Health
  • 6.66. HansaBiomed
  • 6.67. HTG Molecular Diagnostics
  • 6.68. iCellate
  • 6.69. ICON PLC
  • 6.70. Illumina
  • 6.71. Incell Dx
  • 6.72. Inivata
  • 6.73. Invitae Corporation
  • 6.74. Invivogen
  • 6.75. Invivoscribe
  • 6.76. J&J Innovative Medicine
  • 6.77. KEW
  • 6.78. Lucence Health
  • 6.79. Lunglife AI Inc
  • 6.80. MDNA Life SCIENCES, Inc.
  • 6.81. MDx Health
  • 6.82. Menarini Silicon Biosystems
  • 6.83. Mesa Laboratories, Inc.
  • 6.84. Millipore Sigma
  • 6.85. Miltenyi Biotec
  • 6.86. miR Scientific
  • 6.87. Myriad Genetics
  • 6.88. Nanostring
  • 6.89. NantHealth, Inc.
  • 6.90. Natera
  • 6.91. NeoGenomics
  • 6.92. NGeneBio
  • 6.93. Novogene
  • 6.94. Oncimmune
  • 6.95. Oncocyte
  • 6.96. OncoDNA
  • 6.97. OraLiva
  • 6.98. Oxford Nanopore Technologies
  • 6.99. Panagene
  • 6.100. Personalis
  • 6.101. Perthera
  • 6.102. PGDx (Labcorp)
  • 6.103. Precipio
  • 6.104. PrecisionMed
  • 6.105. Predictive Oncology
  • 6.106. Prenetics
  • 6.107. Promega
  • 6.108. Qiagen
  • 6.109. QuidelOrtho
  • 6.110. Rarecells SAS
  • 6.111. RareCyte
  • 6.112. Revvity
  • 6.113. Roche Diagnostics
  • 6.114. Screencell
  • 6.115. Sherlock Biosciences
  • 6.116. Siemens Healthineers
  • 6.117. simfo GmbH
  • 6.118. Singlera Genomics Inc.
  • 6.119. Singular Genomics
  • 6.120. Singulomics
  • 6.121. SkylineDx
  • 6.122. Standard BioTools
  • 6.123. Stilla Technologies
  • 6.124. Sysmex Inostics
  • 6.125. Tempus Labs, Inc.
  • 6.126. Thermo Fisher Scientific
  • 6.127. Todos Medical
  • 6.128. Ultima Genomics
  • 6.129. Variantyx
  • 6.130. Vela Diagnostics
  • 6.131. Veracyte
  • 6.132. VolitionRX
  • 6.133. Vortex Biosciences

7. The Global Market for Cancer Gene Panels and Profiles

  • 7.1. Global Market Overview by Country
    • 7.1.1. Table - Global Market by Country
    • 7.1.2. Chart - Global Market by Country
  • 7.2. Global Market by Cancer Type - Overview
    • 7.2.1. Table - Global Market by Cancer Type
    • 7.2.2. Chart - Global Market by Cancer Type - Base/Final Year Comparison
    • 7.2.3. Chart - Global Market by Cancer Type - Base Year
    • 7.2.4. Chart - Global Market by Cancer Type - Final Year
    • 7.2.5. Chart - Global Market by Cancer Type - Share by Year
    • 7.2.6. Chart - Global Market by Cancer Type - Segment Growth
  • 7.3. Global Market by Application - Overview
    • 7.3.1. Table - Global Market by Application
    • 7.3.2. Chart - Global Market by Application - Base/Final Year Comparison
    • 7.3.3. Chart - Global Market by Application - Base Year
    • 7.3.4. Chart - Global Market by Application - Final Year
    • 7.3.5. Chart - Global Market by Application - Share by Year
    • 7.3.6. Chart - Global Market by Application - Segment Growth
  • 7.4. Global Market by Tissue - Overview
    • 7.4.1. Table - Global Market by Tissue
    • 7.4.2. Chart - Global Market by Tissue - Base/Final Year Comparison
    • 7.4.3. Chart - Global Market by Tissue - Base Year
    • 7.4.4. Chart - Global Market by Tissue - Final Year
    • 7.4.5. Chart - Global Market by Tissue - Share by Year
    • 7.4.6. Chart - Global Market by Tissue - Segment Growth
  • 7.5. Global Market Germline & Somatic - Overview
    • 7.5.1. Table - Global Market Germline & Somatic
    • 7.5.2. Chart - Global Market Germline & Somatic - Base/Final Year Comparison
    • 7.5.3. Chart - Global Market Germline & Somatic - Base Year
    • 7.5.4. Chart - Global Market Germline & Somatic - Final Year
    • 7.5.5. Chart - Global Market Germline & Somatic - Share by Year
    • 7.5.6. Chart - Global Market Germline & Somatic - Segment Growth

8. Global Cancer Gene Panels & Profiles Markets - By Type of Cancer

  • 8.1. Comprehensive Panels & Profiles
    • 8.1.1. Table Comprehensive Testing - by Country
    • 8.1.2. Chart - Comprehensive Testing Growth
  • 8.2. Breast Cancer Gene Testing
    • 8.2.1. Table Breast Cancer Gene Testing - by Country
    • 8.2.2. Chart - Breast Cancer Testing Growth
  • 8.3. Colorectal Cancer Gene Testing
    • 8.3.1. Table Colorectal Cancer Gene Testing - by Country
    • 8.3.2. Chart - Colorectal Cancer Gene Testing Growth
  • 8.4. Gynecological Cancer Gene Testing
    • 8.4.1. Table Gynecological Cancer Gene Testing - by Country
    • 8.4.2. Chart - Gynecological Cancer Gene Testing Growth
  • 8.5. Blood Cancer Gene Testing
    • 8.5.1. Table Blood Cancer Gene Testing - by Country
    • 8.5.2. Chart - Blood Cancer Gene Testing Growth
  • 8.6. Prostate Cancer Gene Testing
    • 8.6.1. Table Prostate Cancer Gene Testing - by Country
    • 8.6.2. Chart - Prostate Cancer Testing Growth
  • 8.7. Lung Cancer Gene Testing
    • 8.7.1. Table Lung Cancer Gene Testing - by Country
    • 8.7.2. Chart - Lung Cancer Gene Testing Growth
  • 8.8. Other Cancer Gene Testing
    • 8.8.1. Table Other Cancer Gene Testing - by Country
    • 8.8.2. Chart - Other Cancer Gene Testing Growth

9. Global Cancer Gene Panels & Profiles Markets - By Type of Application

  • 9.1. Clinical Testing
    • 9.1.1. Table Clinical Testing - by Country
    • 9.1.2. Chart - Clinical Testing Growth
  • 9.2. Pharmaceutical Testing
    • 9.2.1. Table Pharmaceutical Testing - by Country
    • 9.2.2. Chart - Pharmaceutical Testing Growth
  • 9.3. Research Testing
    • 9.3.1. Table Research Testing - by Country
    • 9.3.2. Chart - Research Testing Growth

10. Global Cancer Gene Panels & Profiles Markets - By Tissue Type

  • 10.1. Solid Tissue
    • 10.1.1. Table Solid Tissue Testing - by Country
    • 10.1.2. Chart - Solid Tissue Testing Growth
  • 10.2. Liquid Tissue Testing
    • 10.2.1. Table Liquid Tissue Testing - by Country
    • 10.2.2. Chart - Liquid Tissue Testing Growth

11. Global Cancer Gene Testing Markets - Germline and Somatic

  • 11.1. Global Market Somatic
    • 11.1.1. Table Somatic - by Country
    • 11.1.2. Chart - Somatic Testing Growth
  • 11.2. Global Market Germline
    • 11.2.1. Table Germline - by Country
    • 11.2.2. Chart - Germline Testing Growth

12. Potential Market Opportunity Sizes

  • 12.1. Potential Cancer Screening by Country: Lung, Breast & Colorectal
  • 12.2. Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer
  • 12.3. Potential Market Size - Cancer Diagnosis
  • 12.4. Potential Market Size - Therapy Selection

13. Appendices

  • 13.1. Growth of Approved IVD Test Menu
  • 13.2. Growth of Approved Average IVD Test Fee
  • 13.3. The Most Used IVD Assays
  • 13.4. The Highest Grossing Assays
  • 13.5. Laboratory Fees Schedule